Nomogram to Predict the Probability of Relapse in Patients Diagnosed With Borderline Ovarian Tumors. Issue 2 (1st February 2013)

• Record Type: Journal Article
• Authors: Obermair, Andreas; Tang, Amy; Kondalsamy–Chennakesavan, Srinivas; Ngan, Hextan; Zusterzeel, Petra; Quinn, Michael; Carter, Jonathan; Leung, Yee; Janda, Monika
• Is Part Of: International journal of gynecological cancer. Volume 23:Issue 2(2013)
• Page Start: 264
• Page End: 267
• Publication Date: 2013-02-01
• Subjects: Borderline ovarian tumors -- CA125 -- Survival; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0b013e31827b8844
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: This study aimed to develop a nomogram predicting the probability of relapse in individual patients who have surgery for borderline ovarian tumors (BOTs). Methods: This retrospective study included 801 patients with BOT diagnosed between 1985 and 2008 at 6 gynecologic cancer centers. We analyzed covariates that were associated with the risk of developing a recurrence by multivariate logistic regression. We identified a parsimonious model by backward stepwise logistic regression. The 5 most significant or clinically important variables associated with an increased risk of recurrence were included in the nomogram. The nomogram was internally validated. Results: Fifty-one patients developed a recurrence after a median observation period of 57 months. Age at diagnosis, the International Federation of Gynecology and Obstetrics stage, cell type, preoperative serum CA125, and type of surgery (radical vs fertility-sparing) were associated with an increased risk of recurrence and were used in the nomogram. Bootstrap-corrected concordance index was 0.67 and showed good calibration. Conclusions: Five factors that are commonly available to clinicians treating patients with BOT were used in the development of a nomogram to predict the risk of recurrence. The nomogram will be useful to counsel patients about risk-reduction strategies to minimize the risk of recurrence or to inform patients about a very low risk of recurrence making intensive follow-up unwarranted.